Shares of ChemoCentryx (NASDAQ: CCXI) were cratering by 58.3% as of 11:40 a.m. EDT on Friday. The stock also crashed on Tuesday after the U.S. Food and Drug Administration (FDA) released briefing documents for an advisory committee that expressed significant reservations about the company's data for avacopan. Today's huge decline came after that advisory committee's vote on recommending approval for the experimental therapy.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting